So my friend, Justin Morgenstern recently put up a post on Idarucizumab, aka Praxbind. He seemed pretty fired up on the issue, so I got him on the line to talk about it. What follows is a conversation on evidence and what to do when there is not a good amount of it.
Justin Wrote an Additional Post after our Discussion
On to the Wee…
Latest posts by Scott Weingart (see all)
- EMCrit RACC 228 – Physiology-Guided Cardiac Arrest Management in 2018 with Dr. Robert Sutton - July 11, 2018
- EMCrit RACC – A Refractory Anaphylaxis Mock Trial by Mike Weinstock - July 5, 2018
- EMCrit Podcast – Acid Base Ep. 7 – Bicarb Updates, Quantitative Approach, and Prof. David Story - June 28, 2018